Your browser doesn't support javascript.
loading
LOT and HOT … or not. The proliferation of clinically insignificant and poorly characterised types of renal neoplasia.
Samaratunga, Hemamali; Egevad, Lars; Thunders, Michelle; Iczskowski, Kenneth A; van der Kwast, Theodorus; Kristiansen, Glen; Pan, Chin-Chen; Leite, Katia R M; Evans, Andrew; Clouston, David; Kenwright, Diane N; Bethwaite, Peter B; Malone, Greg; Wood, Simon; Yaxley, John W; Delahunt, Brett.
Afiliação
  • Samaratunga H; Aquesta Uropathology, Brisbane, Qld, Australia; University of Queensland, Brisbane, Qld, Australia.
  • Egevad L; Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden.
  • Thunders M; Department of Pathology and Molecular Medicine, Wellington School of Medicine and Health Sciences, University of Otago, Wellington, New Zealand.
  • Iczskowski KA; Department of Pathology, Medical School of Wisconsin, Milwaukee, WI, USA.
  • van der Kwast T; Laboratory Medicine Program, University Health Network and Princess Margaret Cancer Center, Toronto, Canada.
  • Kristiansen G; Institute of Pathology, University Clinic, Bonn, Germany.
  • Pan CC; Department of Pathology, Taipei Veterans General Hospital, Taipei, Taiwan.
  • Leite KRM; Department of Urology, Laboratory of Medical Research, University of São Paulo Medical School, São Paulo, Brazil.
  • Evans A; Department of Pathology, Mackenzie Health, Richmond Hill, Ontario, Canada.
  • Clouston D; TissuPath, Waverley, Vic, Australia.
  • Kenwright DN; Department of Pathology and Molecular Medicine, Wellington School of Medicine and Health Sciences, University of Otago, Wellington, New Zealand.
  • Bethwaite PB; Department of Pathology and Molecular Medicine, Wellington School of Medicine and Health Sciences, University of Otago, Wellington, New Zealand; Southern Community Laboratories, Wellington, New Zealand.
  • Malone G; Royal Brisbane Hospital, Brisbane, Qld, Australia.
  • Wood S; Department of Urology, Princess Alexandra Hospital Brisbane, Qld, Australia.
  • Yaxley JW; University of Queensland, Brisbane, Qld, Australia; Wesley Hospital, Brisbane, Qld, Australia.
  • Delahunt B; Aquesta Uropathology, Brisbane, Qld, Australia; Department of Pathology and Molecular Medicine, Wellington School of Medicine and Health Sciences, University of Otago, Wellington, New Zealand; Southern Community Laboratories, Wellington, New Zealand. Electronic address: brett.delahunt@otago.ac.nz.
Pathology ; 54(7): 842-847, 2022 Dec.
Article em En | MEDLINE | ID: mdl-36270849
ABSTRACT
The classification of malignant tumours is influenced by both immunohistochemical and molecular genetic findings. This is highlighted in the latest World Health Organization classification of renal neoplasia, which has a tumour category of 'tumours that are molecularly defined'. This implies that the defining molecular features are integral to tumourigenesis, which may not necessarily be the case. Renal oncocytoma is recognised as a benign tumour with variable morphology and immunoexpression. A variant of these tumours is hybrid oncocytic chromophobe tumour, which has features of both oncocytoma and chromophobe renal cell carcinoma and may, on rare occasions, show malignant behaviour. Recent reports have proposed two further entities with eosinophilic cytoplasm and varying nuclear pleomorphism, designated low grade oncocytic tumour (LOT) and eosinophilic vacuolated tumour (EVT), formally known as high grade oncocytic tumour (HOT). The diagnosis of these apparently benign tumours was made on the basis of morphological and immunohistochemical features. More recently it has been claimed that the mutations in the mTOR pathway are also a diagnostic feature and it is further suggested that these mutations are key to the pathogenesis of these tumours. As is seen in oncocytoma, immunohistochemical expression of tumours included in series of LOT and EVT is variable. The mutations in the mTOR pathway, where detected, were not constant, with any combination of mTOR, TSC1 and/or TSC2 being involved. A major issue is that in many of the studies full comparative genomic hybridisation results are not presented. In addition it is well recognised that mTOR mutations are seen in a variety of renal tumours. In view of these conflicting results, the rarity of these tumours and their apparent benign nature, raises questions as to why these tumours should be considered specific entities.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Adenoma Oxífilo / Neoplasias Renais Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Adenoma Oxífilo / Neoplasias Renais Idioma: En Ano de publicação: 2022 Tipo de documento: Article